This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Nov 2015

Allergan reaches settlement with New York Attorney General's Office in memantine immediate release litigation

Company admits no liability, has released its counterclaims against New York, and has agreed to make a payment of approximately $172,000.

Allergan has reached an agreement with the New York State Attorney General's Office to end the litigation under Section 2 of the Sherman Act, and other statutes with the Attorney General over the decision of Forest Laboratories, Inc., announced in February 2014, to cease marketing and selling the now generic version of memantine immediate release tablets. Under the terms of settlement, Allergan admits no liability, has released its counterclaims against New York, and has agreed to make a payment of approximately $172,000 to the State of New York to help defray a portion of the state's litigation expenses. In addition, Allergan withdraws its petition for a writ of certiorari, filed in the Supreme Court of the United States, challenging the decision of the US Court of Appeals for the Second Circuit in New York v. Actavis plc, No. 14-4624 (22 May 2015).

"The settlement announced today ends this litigation, and ends the appellate proceedings at the US Supreme Court. The Company believes that the novel and unprecedented legal holding in the Court's decision is limited to the facts and findings in this particular case," said Robert Bailey, Executive Vice President and Chief Legal Officer at Allergan. "We remain committed to clarifying the law in this area along the lines set forth in the Company's petition for certiorari with the Supreme Court of the United States, which was filed on 4 November 2015, and we expect that there will be opportunities to do so in the future."

Related News